11 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 11 of 11 clinical reviews.
A guide for caregivers administering zolpidem (Ambien) to adults 65 and older, covering FDA-recommended doses, fall and cognitive risks, safe administration steps, and when to call the prescriber.
A clinical guide to managing zolpidem use in adolescents aged 12 to 17 as they transition to adult care, covering FDA labeling, safety data, dosing adjustments, and care-coordination strategies.
How zolpidem (Ambien) affects school performance, sports, driving, and daily activities in teenagers ages 12 to 17. Evidence-based guidance from the HealthRX.com medical team.
A clinical review of zolpidem (Ambien) use in geriatric patients aged 65+, covering pharmacokinetic changes with aging, cognitive and fall risks, Beers Criteria guidance, safer alternatives, and dosing recommendations backed by primary sources.
A clinical guide to zolpidem use in geriatric patients, covering FDA-approved dosing, off-label prescribing patterns, fall and cognitive risks, Beers Criteria warnings, and evidence-based alternatives for older adults.
A guide to zolpidem use in geriatric patients aged 65 and older, covering fall risk, next-day sedation, driving, exercise, cognitive effects, and safer sleep alternatives supported by current evidence.
A clinically detailed guide to zolpidem use, risks, dosing, and safer alternatives for adults 65 and older, including guidance on transitioning from geriatric to general adult care protocols.
Zolpidem (Ambien) is not FDA-approved for children under 12. Learn what the evidence says, why pediatric use carries serious risks, and what caregivers should do instead.
Zolpidem is not FDA-approved for children under 12. Learn what the evidence says about next-day sedation, school performance, and physical activity risks when zolpidem is used off-label in pediatric patients.
A clinical review of zolpidem's developmental impact in children under 12, covering FDA trial data, neurodevelopmental risks, off-label prescribing patterns, and safer evidence-based alternatives for pediatric insomnia.
A clinical review of zolpidem (Ambien) off-label use in pediatric patients under age 12, covering evidence, risks, dosing considerations, and safer alternatives supported by current guidelines.